Medical Journal Publications:
Association of Reproductive Health Professionals
|
|
A New View of Women's Sexual Health in Midlife and Beyond
May 2005: "A botanical feminine massage oil formulated to enhance female sexual pleasure and arousal when applied to the vulva,
Zestra®
was compared in a randomized, doubleblind, crossover study with placebo oil in 10 women with and 10 women without female sexual arousal disorder
(FSAD). Both women with and without FSAD showed statistically significant improvements compared with placebo in levels of arousal and
desire, satisfaction with arousal, genital sensation, the ability to have orgasms, and sexual pleasure. A greater response was found in
women with the disorder compared with women who did not complain of arousal problems."
View the entire A New View of Women's Sexual Health in Midlife and Beyond Excerpt
|
|
Female Sexual Dysfunction: Principles of Diagnosis and Therapy
|
|
March 2005, Obstetrical and Gynecological Survey published a Continuing Medical Education (CME) Review Article that acknowledges
the benefits of Zestra® for both arousal and orgasmic difficulties. The objective of the CME Review Article titled "Female Sexual
Dysfunction: Principles of Therapy" is to provide the most current clinical information available to Obstetricians and Gynecologists on
the topic of female sexual dysfunction and the principles of diagnosis and therapy.
The CME Review Article cites a clinical trial conducted by QualiLife Pharmaceuticals titled "Randomized Placebo-Controlled Double Blind,
Crossover Design Trial of the Efficacy and Safety of Zestra® for Women in Women With, and Without Female Sexual Arousal Disorder
(FSAD)."
The study of 20 women showed improvement in level of desire, arousal, sensation, pleasure and ability to have orgasms in both normal and
FSAD patients using Zestra®, as compared with placebo. Zestra® is the only product listed in the CME Review Article that has
published clinical study results and no known negative effects.
View the entire CME - Female Sexual Dysfunction: Principles of Diagnosis and Therapy PDF
|
|
Dietary supplements for female sexual dysfunction
|
|
"A randomized, double-blind, placebo-controlled trial studied the effects of Zestra in 20 women with and without FSAD.23 Applicants were
evaluated with the FSFI and FSDS questionnaires. Women with FSAD had baseline scores of 4060 on the FSDS, and non-FSAD women had
baseline scores of <40 on the FSDS. (The FSDS ranges from 0 to 80, with lower scores generally indicating normal function.) All
participants were allowed to continue current medications, including antidepressants, nutritional supplements, and hormone replacement
therapy. Sexual pain or an FSDS score of >60 would exclude patients from participation. Each patient was given five vials of Zestra or
placebo and a diary (the Female Sexual Encounter Profile [FSEP]). After the patients used all five vials, they returned and completed
the FSFI, the FSDS, two global assessment questionnaires (GAQs), and the QualiLife Consumer Testing Survey (QCTS). Then they received
the crossover vials and a new diary and returned to complete the questionnaires again. Zestra produced significant improvement in FSEP,
FSFI, GAQ, and QCTS scores. The primary outcome measure, sexual arousal, showed a mean ± S.D. improvement (on a 01 scale) of 0.22 ±
0.28 (p = 0.03). There were no significant changes in FSDS scores. In addition, the researchers compared data between patients taking
and not taking SSRIs; there was no significant difference. It was concluded that Zestra improved sexual function in all subjects,
regardless of FSAD diagnosis or SSRI use. Some patients reported that Zestra caused mild burning or tingling that resolved within 30
minutes. No other adverse effects were reported."
View the American Journal of Health Full-Text Article.
View the American Journal of Health PDF.
View the Pub
Med abstract. |
|
The National Association of Nurse Practitioners in Women's Health - A Practical Journal for Nurse Practitioners
|
|
"I can't tell you how many patients I've also heard from, expecially when, everywhere they turn, from Forbes to Redbook,
they (or their
significant other) read about a supposedly "harmless" natural product that claims to enhance desire, arousal, lubrication, orgasm, and satisfaction. This prompts me to quote a common
adage, "If it sounds too good to be true, it probably is."
View the entire Women's Health Care Article
|
|
|
|
Female Sexual Dysfunction - Potential for Pharmacotherapy
"The act of sex includes a woman's sexual self and self-image, intimate relationships, family, society and culture. The complexities of
her
environment, sexual and partner history, past relationships, mental health status, current medical problems and hormonal status all play a role. An
interdisciplinary consensus conference panel expanded the former Diagnostic and Statistical Manual of Mental Disorders-IV classifications of female
sexual dysfunction to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders that cause personal
distress..."
View Excerpts from the Drugs Journal Article
|
|
Featured In:
  
* Click on one of the above logos to view it's article details.
|
|
